In their cohort, Dr. Abarza et al reported a small percentage of pts developing PsA before Pso (8.6%) This group also had faster radiographic progression vs. the Pso before PsA group.....something to consider when evaluating these pts. @rheumnow #ACR24 abs2328 https://t.co/YPcAaKFS2I

Quote of the day. “Time is kidney” Maria Dall’Era MD, UCSF at the ACR SLE guidelines for management of lupus nephritis @RheumNow #ACR24 https://t.co/rz9AhPS2cl

A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes Key findings: - Significant weight loss after starting IL17i, IL23i, and csDMARDs. - TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn

#2286🔬Certolizumab Pegol (CZP) in High RF RA 📊Pooled analysis;N=1180 💥PBO: High RF=more radiographic progression v low RF (Wk24 6.5 v 2.8%,Wk52 17.6 v 10.4%) 💥CZP: min. progression regardless of RF (Wk24 0 v 1.1%;Wk52 5.3 v 3.1%) #ACR24 @RheumNow https://t.co/koel7SDsUb

Triboulet et al. JAKi in RA-ILD. 42 patients. Stability of PFTs over median 21 months. HRCT stable in 62%. Progressive ILD on HRCT in 19%. @RheumNow #ACR24 Abstr#2249 https://t.co/PY9BrCfNHc https://t.co/r8fIgrjyDu

Tesser et al. Implanted cervical vagus nerve stimulator for b/tsDMARD-IR RA. 242 patients. ACR20 week 12 35% vs 24%. Higher rates of DAS28-CRP LDA/remission. @RheumNow #ACR24 Abstr#L10 https://t.co/OXojHEMkKQ https://t.co/XSt97u7LrR

Long COVID outcomes in Autoimmune diseases (AID) Abstract 1897: - Long COVID symptoms higher among AID pts vs controls - vaccinated may have protective benefit @RheumNow #ACR24 https://t.co/2SEcbkxfcU

Important study in SLE: out of 590 pts with pericarditis, 20% had recurrence w/in 1 year Higher in early dx, younger pts, higher dx activity, & pred exposure Is prednisone risk confounding by indication? Or causative? #ACR24 @RheumNow @andreafava Abstr#2372 https://t.co/Seyi4F6weY

@DianeLacaille Canadian biosimilar exp Biosimilar transition v originator controls x2 yrs Weighted model: no decr in ETN biosimilar discontinuation v originator. IFX shows slight decrease - NOT statistical signif Safety- no difference, slight incr rheum visits @RheumNow #ACR24 https://t.co/0GMfLAyzOo

Ren et al. XG005, compound with NSAID and neuropathic like effects, in knee OA. At week 4 significant improvements in WOMAC pain, stiffness, function, and primary endpoint of walking pain @RheumNow #ACR24 Abstr#L08 https://t.co/gQDwAmzI4G https://t.co/b22XC7rXnE

Depressing finding re:glucocorticoid discontinuation in SLE No improvement over decades in rate of GC discontinuation; if anything, we start more GC than ever @AliDuarteMD help me out here; why haven't we made more progress? #ACR24 @RheumNow Abstr#2421 https://t.co/uzZATKPWVC